Additional file 1 of Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

Additional file 1: Table S1. Summary of comorbidities in ≥ 5% patients in FAS. Table S2. Investigator-assessed efficacy of iruplinalkib in FAS. Figure S1. Waterfall plots of the subgroup BOR of target lesions by IRC in FAS. Figure S2. Waterfall plot of BOR by investigator in FAS. Figure S3. Swimmer plot of iruplinalkib exposure and response by investigator in FAS. Figure S4. Minimum plasma iruplinalkib concentration at each time point in the pharmacokinetics analysis set.